STRATA Skin Sciences, Inc. · OTC:SSKN
STRATA Skin Sciences — Investor Presentation (December 2024)
37 slides from STRATA Skin Sciences's investor presentation, Dec 11, 2024
Slide 1: Driving Value in Dermatology
Investor Presentation December 2024 Driving Value in Dermatology Matching Patients with Clinics for a Win-Win-Win Outcome NASDAQ: SSKN
Slide 2: Safe Harbor Statement
Safe Harbor Statement 2 This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be
Slide 3: About Us
About Us 3 STRATA Skin Sciences is a medical technology company offering advanced medical devices for the in-office treatment of life-altering dermatological conditions. $38B Market Opportunity Across Psoriasis, Vitiligo, Eczema, and Acne markets Experienced Management with 20+ Year History in Der
Slide 4: Addressing $38B Dermatology Market
Addressing $38B Dermatology Market Psoriasis - $20.1B1, Vitiligo - $1.2B2, Eczema - $11.8B3, Acne - $5.5B4 4 30M Patients in the U.S. Psoriasis – 8M / Vitiligo - 5M / Eczema - 18M Fortune Business Insights Market Report 2019; 2016-2018 historical, 2019 base year, 2020-2027 projected Fortune Business
Slide 5: Affiliated Academic Institutions
Affiliated Academic Institutions STRATA has placed over 50 XTRAC® machines in residency programs across academic institutions 5 Affiliated Academic Institutions STRATA devices are available at over 50 academic institutes that offer dermatology residency programs 5
Slide 6: Management Team
Management Team Sales and Operational Dermatology Experience Chief Executive Officer Dr. Dolev Rafaeli V.P. Finance John Gillings Chief Operating Officer Shmuel Gov 6
Slide 7: STRATA Investment Highlights
STRATA Investment Highlights 7 Unique and Proven Business Model Best-in-class Excimer Laser technologies Recurring revenue driven by DTC and growing installed base Installed base of 873 XTRAC® domestic devices for Psoriasis, Vitiligo, and Eczema treatments Installed base of 135 TheraClear®X domestic
Slide 8: 3Q24 Financial Highlights
3Q24 Financial Highlights 8 Revenue Total revenue $8.8M (-1% YOY) vs. $8.9M 3Q23 Global net recurring revenue $5.4M (+2% YOY) vs. $5.3M 3Q23 Gross domestic XTRAC® recurring billings $4.8M (-2% YOY) vs. $4.9M 3Q23 Revenue per domestic XTRAC® system $5,332 (+2% YOY) on 873 systems vs. $5,233 on 929 sy
Slide 9: Core Domestic Business Model
Core Domestic Business Model
Slide 10: A True Partnership – A Complete Business Solution
A True Partnership – A Complete Business Solution 10 No upfront capital expense; instead, it’s a fee-per-use business model Complete business solution includes a suite of value-added support services to maximize practice’s success Clinical Support Reimbursement Support Call Center Support Field Serv
Slide 11: ~900 Partner Dermatology Clinics with 3,000+ Providers Across the U.S.
~900 Partner Dermatology Clinics with 3,000+ Dermatology Providers Across the U.S. 11 Overview 873 Partner XTRAC® clinics + >150 sold XTRAC® devices 135 TheraClear®X clinics 3 Regions / 23 Sales Territories / 1 National Accounts Manager 15 Field Service Techs In-house call center and insurance bene
Slide 12: Practice Development Program
Practice Development Program In-Office Patient Education Materials for psoriasis, vitiligo & atopic dermatitis: Patient Brochures Counter Cards In Office Branding “Patient-Directed” marketing initiative: Patient Education Mailings Outreach Programs Eblasts 12 12
Slide 13: Marketing Support Drives Additional Patient Awareness
Marketing Support Drives Additional Patient Awareness 13 Patient Eblasts Direct Mailers In-office Branding Social Media Trade Shows Clinical Webinars
Slide 14: DTC Advertising Generates Direct and Indirect Appointments in Partner Clinics
DTC Advertising Generates Direct and Indirect Appointments in Partner Clinics 14 See XTRAC® ad on Facebook, Google and Instagram Click on the ad to go to an XTRAC® page Leave their contact information In-house call center team confirms appointment and insurance benefits Show in the office Convert to
Slide 15: Core Business Refocused to Drive Recurring Revenue Model
Leads Appointments RDX Charts (New Patient Charts) 1 2 1 3 DTC Model Driver 15 Core Business Refocused to DRIVE Recurring Revenue Model $21.1M Net U.S. Recurring Revenue Significant opportunity to increase ARR back to 2019 levels using proven DTC strategies that should yield appreciable incremental
Slide 16: International Sales Operations
International Sales Operations India Israel S. Korea Japan China Bahrain, Iraq, Jordan, Kuwait, Qatar, Oman, Saudi Arabia, UAE Mexico In-house Head of International Sales 39 international partner XTRAC® clinics (S. Korea, Japan) at 9/30/24 Capital equipment sales preferred model Usage per device hig
Slide 17: XTRAC®: Overview
XTRAC®: Overview Safe, effective treatment 150+ peer-reviewed clinical studies Psoriasis treatment is the number 1 domestic use for XTRAC® lasers – 80% of treatments Opportunities exist for expanding use for other approved indications like vitiligo and eczema Clinical support team focused on: In-off
Slide 18: Indicated for Chronic Dermatological Diseases
Indicated for Chronic Dermatological Diseases Visible skin disorders can limit healthy psychosocial development and have profoundly negative consequences on quality of life3-5 VITILIGO ~7.5 million adults in the US1,a PSORIASIS ATOPIC DERMATITIS ~2–3 million adults in the US2 ~16.5 million adults in
Slide 19: Induces Apoptosis of T cells and Keratinocytes in Psoriatic Plaques
Induces Apoptosis of T cells and Keratinocytes in Psoriatic Plaques 19 Baseline After 2 tx After 4 tx XTRAC® Psoriasis Clinical Protocol - 6.2 treatments to PASI* 75 Induces apoptosis in T cells and keratinocytes1 T cell Keratinocytes Psoriasis: Autoimmune disease that causes the skin to regenerate
Slide 20: Induces Melanocyte Proliferation and T cell Apoptosis in Vitiligo Patches
Induces Melanocyte Proliferation and T cell Apoptosis in Vitiligo Patches 20 Baseline After 18 tx After 21 tx XTRAC® Vitiligo Clinical Protocol - >75% repigmentation in less than 20 treatments1 Vitiligo: An autoimmune condition due to a loss of melanocytes, characterized by white patches of skin los
Slide 21: XTRAC® is a Preferred Treatment for 90% of Psoriasis Patients
Source: National Psoriasis Foundation XTRAC® is a Preferred Treatment for 90% of Psoriasis Patients (<10% BSA) 21
Slide 22: Has Clinical and Economic Competitive Advantage
Has Clinical and Economic Competitive Advantage 22 XTRAC® NB-UVB Topical Steroids Non-Biologic Systemics Biologics Approximate Costs ($) 1K-3K 3K-9K 1K-7K 1K 32K-68K Clinical Outcomes 92% 71% 75% 48% 50-70% Speed of Onset 5 10 3 14 12 Days of Actual Care 18 80 294 52 12-65 Remission 2.5 Months Conti
Slide 23: XTRAC® Adds Reimbursed Recurring Revenue for Dermatology Partners
XTRAC® Adds (Delegated)* Reimbursed Recurring Revenue for Dermatology Partners 23 CPT Code Description 2024 National Average Medicare Payment Rate 96920 Excimer Laser Treatment for Psoriasis (<250 sq cm) $152.92 96921 Excimer Laser Treatment for Psoriasis (250 - 500 sq cm) $167.65 96922 Excimer Lase
Slide 24: TheraClear®X: Overview
TheraClear®X: Overview Safe, effective treatment Peer-reviewed clinical studies Opportunities exist for expanding use for expanding the installed base to clinics using reimbursed acne surgery procedures Clinical support team focused on: In-office training Best practices 24
Slide 25: Acne is the Most Common Skin Condition in Dermatology
Acne is the Most Common Skin Condition in Dermatology Up to 50 Million Americans affected annually2 ~85% of all adolescents experience some degree of acne from the ages of 12 to 24 years3 >50% of US women experience acne in their 20s4 Acne occurring in adults is increasing5 #1 skin disease in the US
Slide 26: Photopneumatic Technology Combines Vacuum with Pulsed Broadband Light
Photopneumatic Technology Combines VACUUM with PULSED BROADBAND LIGHT 26 Clears bacteria and follicular contents from pilosebaceous unit, C acnes are removed both mechanically and thermally from the active acne lesion. Reduces sebum production cleans pores by extracting sebaceous and follicular mate
Slide 27: Addresses Limitations of Existing Acne Therapies
Addresses Limitations of Existing Acne Therapies 27 Visible improvement of acne lesions as early as after second treatment Visible improvement of skin texture, pore size, and perilesional erythema after the first few treatments Time to improvement Initiation 4 to 6 treatments, scheduled 1-2 weeks ap
Slide 28: TheraClear®X Adds Reimbursed Recurring Revenue for Dermatology Partners
TheraClear®X Adds (Delegated)* Reimbursed Recurring Revenue for Dermatology Partners 28 CPT Code Description 2024 National Average Medicare Payment Rate 10040 Acne Surgery, which Involves the opening or removal of multiple milia, comedones, cysts and pustules. $114.61 Number of Treatment/ Week 20 30
Slide 29: Summary
SUMMARY STRATA
Slide 30: Financial Metrics
Financial Metrics Unaudited quarterly results 30 2019 2020 2021 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 FY 2023 Q1 2024 Q2 2024 Q3 2024 U.S. Gross Recurring Revenue $24,590 $16,901 $22,071 $22,271 $4,735 $5,057 $4,883 $4,947 $19,622 $4,578 $4,735 $4,799 U.S. Installed Base (XTRAC® Devices) 820 832 890
Slide 31: STRATA Investment Summary
STRATA Investment Summary Unique and Proven Business Model Best-in-class Excimer Laser technologies Recurring revenue driven by DTC and growing installed base Installed base of 873 XTRAC® domestic devices for Psoriasis, Vitiligo, and Eczema treatments Installed base of 135 TheraClear®X domestic devi
Slide 32: Thank You!
THANK YOU! Investor Contact: CORE IR 516-222-2560 [email protected] www.strataskinsciences.com
Slide 33: Appendix
APPENDIX SKIN SCIENCES
Slide 34: Acquisitions to Drive Top-line Growth
Acquisitions to Drive Top-line Growth January 2022 August 2021 $3.7M Acquisition Minimal acquisition cost compared to exclusivity in external laser market $1M Acquisition Adds attractive business segment to address $5.5B acne market 34
Slide 35: Domestic XTRAC® Installed Base Growth Drivers
Domestic XTRAC® Installed Base Growth Drivers 873 2286 370 As of 9/30/2024 Signed strategic expansion into group clinic rollups Within the 48 groups: 61 TheraClear®X devices Penetration grew from 86 in 2018 to 386 in 2023 Group partnership accounts represent 37% of XTRAC® domestic recurring revenue
Slide 36: Example – NYC Metro Area XTRAC® Placements and DTC Leads (1Q24)
Example – NYC Metro Area XTRAC® Placements and DTC Leads (1Q24) 36 Metro NYC XTRAC® installed base Metro NYC 1Q24 DTC Patient Leads
Slide 37: Psoriasis Case Study: Patient I.B., Lewisburg, PA
Psoriasis Case Study: Patient I.B., Lewisburg, PA 37 Treatment Room After Before
STRATA Skin Sciences — Investor Presentation (December 2024) on 6ix